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Background Medication alert overrides remain persistently high over the past
decade, inﬂuenced by factors such as “alert fatigue” and lack of provider acceptance.
Objective We compared the aggregate rate of ﬂuoroquinolone (FQ) prescribing for
the treatment of acute sinusitis, acute bronchitis, and uncomplicated urinary tract
infections (UTIs) in adult inpatients prior to (historical control group) and after
(prospective intervention group) implementation of a program requiring indication
when ordering FQ antibiotics in combination with a nonmodal best-practice alert
regarding the latest U.S. Food and Drug Administration (FDA) recommendations. We
then compared rates of prescribing among provider type, severity of infection, and
patient age.
Methods Qualiﬁed orders were deﬁned as new FQ orders for acute sinusitis, acute
bronchitis, and uncomplicated UTI for adult inpatients between July 2016 through
September 2016 (control) or November 2016 through January 2017 (intervention).
The primary endpoint was a provider-initiated FQ order for a target indication.
Secondary endpoints included FQ orders by provider type and patient age. Rates of
FQ use among the target indications were compared between groups by chi-square test
of independence with Yates’ correction in the analysis of the primary endpoint and
Fisher’s exact test for secondary endpoints.
Results FQ prescribing for acute bronchitis, and uncomplicated UTI occurred at a rate
of 86/350 (24.6%) and 62/394 (15.7%) in the control and experimental groups,
respectively (p ¼ 0.0035). No patients receiving FQ qualiﬁed for a diagnosis of acute
sinusitis.
Conclusion A program combining FQ restriction in combination with nonmodal
messaging may have decreased the rate of prescribing for acute bronchitis and
uncomplicated UTI, although the contributions of each individual element could not
be rigorously assessed.
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Background and Signiﬁcance
The Medicare and Medicaid Electronic Health Record (EHR)
Incentive Program has established “meaningful use” requirements for clinical decision support (CDS) with the intent of
providing evidence-based interventions to reduce adverse drug
events.1 Despite implementation of these meaningful use
requirements for drug–drug and drug–allergy interaction alerts
starting in 2011, analyses of medication order alerts have
shown persistently high override rates over the past decade.2
The term “signal-to-noise ratio” is often used to refer to the ratio
of relevant data to irrelevant data in CDS alerting. Desensitization due to poor signal-to-noise ratios of alerts has been thought
to lead to “alert fatigue” increased alert override rates.2–7
A recently published meta-analysis revealed only two
modiﬁable factors associated with improving patient outcomes related to CDS: providing advice to both practitioners
and patients and requiring practitioners to justify their
overrides of advice.8 Lack of acceptance of CDS by providers
and persistently high override rates raise concerns regarding
the long-term impact of modal alerts (e.g., interruptive alerts
requiring the user to override a warning before continuing to
interact with the EHR) on physician behavior.2 Overrides due
to alert fatigue may result in clinically relevant data being
ignored and potential interventions being missed.4 Noninterruptive best-practice messaging, in conjunction with programmatic changes, may offer an alternative which has not
been previously investigated.
Aside from CDS, many antimicrobial stewardship efforts to
inﬂuence antibiotic prescribing practices have focused on
restriction protocols.9–11 Antimicrobial prescribing with an
optimized antimicrobial stewardship program has been found
to be effective in increasing compliance with institutional
policies, reducing duration of antibiotic treatment, and associated with concomitant decreased levels of bacterial resistance to drug classes such as ﬂuoroquinolones (FQs).9,10,12 In
May 2016, the U.S. Food and Drug Administration (FDA)
advised restricting FQ for acute sinusitis, acute bronchitis,
and uncomplicated urinary tract infection (UTI) due to disabling and potentially permanent side effects involving the
tendons, muscles, joints, nerves, and central nervous system.13
At Harnett Health System (HHS), a rural academic health
care system, antimicrobial stewardship (AS) strategies at HHS
include prospective audits of antimicrobial use, de-escalation
of therapy based on culture and sensitivity data, dose optimization, intravenous (IV) to per os (PO) conversion, and antimicrobial restriction. Levoﬂoxacin and ciproﬂoxacin are the
only FQs available through the HHS formulary regardless of
indication. Restricted antibiotics require an indication for use
upon ordering and may be initiated with pharmacist review
pending infectious disease consult. Provided indications are
visible to pharmacists for order review prior to veriﬁcation. FQ
restriction was initiated concurrently with implementation of
nonmodal best-practice messaging (e.g., noninterruptive
alerts allowing the provider to continue to interact with
the EHR) embedded into the ordering process to both advise
practitioners and require rationale for antibiotic use by documenting indication.
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The impact of an AS strategy combining a restriction with
best-practice messaging to providers in a rural health setting
has not been reported previously. We therefore sought to
examine the composite effect of implementing systematic AS
initiatives augmented by targeted nonmodal messaging,
speciﬁcally in reducing inappropriate FQ orders for uncomplicated infections. We hypothesized that such a program
would be effective in optimizing FQ prescribing.

Objective
We compared the aggregate rate of formulary FQ prescribing
among adult patients prescribed antibiotics for the treatment
of acute sinusitis, acute bronchitis, and uncomplicated UTI in
adult inpatients prior to (control group) and after (experimental group) implementation of a restriction program augmented by targeted nonmodal messaging. We furthermore
examined the rate of FQ prescribing patterns by provider type,
complication of infection, and patient age.

Methods
Setting
HHS is a rural health system, including two teaching hospitals with a total of 151 beds located in Harnett County, North
Carolina, United States. HHS uses MEDITECH as its electronic
medical record at both hospitals across all inpatient and
emergency departments as a means of computerized provider order entry (CPOE) and CDS, medication administration
documentation, and laboratory result review.

Design
This single-center, historical control and prospective cohort
study was reviewed and exempted by the Cape Fear Valley
Health System Institutional Review Board. FQ orders for adult
inpatients admitted between July 2016 through September 2016
(control) or November 2016 through January 2017 (intervention) were adjudicated using the MEDITECH software and
screened for eligibility. Nonmodal best-practice messaging
was implemented into the EHR by informatics staff and communicated to staff via email, leadership, and through the
Pharmacy & Therapeutics committee. The nonmodal messaging
provided a prominent FDA advisement, as shown in ►Fig. 1,
above the free-text restricted antibiotic ﬁeld as part of the order
process.
Data were extracted through MEDITECH reporting using
ﬁltered queries for provider orders by date for levoﬂoxacin
formulations (PO and IV) with strengths of 250, 500, or
750 mg, or ciproﬂoxacin formulations with strengths of
200 (IV), 400 (IV), 250 (PO), or 500 mg (PO). Orders from
patients with complicated infections, those with one-time
emergency department orders not continued as an inpatient,
or continuation of home therapy for indication of sinusitis,
bronchitis, or uncomplicated UTI were excluded from the
analysis. The diagnoses of acute sinusitis, acute bronchitis, or
uncomplicated UTI were included based on ICD-10 diagnosis
codes (J01, J20, J40, J44, J47, and N39, respectively). Uncomplicated UTI was deﬁned as episodes of acute cystitis or
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Fig. 1 Screenshot of provider ordering screen, including required indication textbox with nonmodal Food and Drug Administration (FDA)
warning message above.

pyelonephritis occurring in healthy premenopausal, nonpregnant women with no history suggestive of an abnormal
urinary tract.14 Complicated UTI was deﬁned as an infection
in the upper or lower urinary tract not meeting criteria for
uncomplicated UTI including male patients, catheter-associated infections, critical care unit patients, sepsis, or concomitant bacterial infections other than the genitourinary
tract.14 Patient visit identiﬁers were collected for all FQ
orders and ICD-10 codes matching selected diagnoses.
Patient visit identiﬁers were then cross-referenced from
each list to provide the population of interest. Chart reviews
were conducted to clarify diagnoses and verify inclusion
criteria.

Data Collection and Analysis
Data collected included FQ dose, formulation, indication,
patient age, and ordering provider. The primary endpoint
was deﬁned as the prescribing of a FQ for the target indication (acute sinusitis, acute bronchitis, or uncomplicated UTI).
A rate of FQ prescribing was determined among all antibiotic
orders for the target indications within the group. Secondary
endpoints were deﬁned as the rates of FQ orders within each
group by provider type, complication, and patient age.
Aggregate rates of FQ orders of the control and prospective cohorts were compared using chi-squared test of independence with Yates’ correction to reduce errors of
approximation. Secondary endpoints were analyzed using
Fisher’s exact test. Statistical signiﬁcance was predeﬁned as a
two-tailed α  0.05. Medication orders missing indication

data were excluded from analysis. Data were analyzed using
JMP version 10.0.

Results
A total of 744 patients were identiﬁed with a diagnosis of acute
bronchitis, or uncomplicated UTI with 350 patients and 394
patients in the control and intervention cohorts, respectively.
No patients receiving FQ therapy qualiﬁed for a diagnosis of
acute sinusitis within the data collection period. Patient
demographics and descriptions of FQ prescribing (dose, indication, and route) are summarized in ►Table 1. Eighty-six and
62 FQ orders were initiated within the cohorts, respectively,
and consisted primarily of high-dose parenteral levoﬂoxacin
indicated for acute bronchitis (see ►Table 1). The rate of FQ
prescribing among the study groups are summarized
in ►Table 2. FQ prescribing for uncomplicated infections
decreased from 24.6 to 15.7% (p ¼ 0.0035). As shown
in ►Fig. 2, FQ orders were at their lowest for acute bronchitis
and uncomplicated UTI during the ﬁrst month following the
incorporation of nonmodal best-practice messaging and antimicrobial restriction. Prescribing of cephalosporins, macrolides, and penicillins increased over the same period
(see ►Table 2). FQ prescribing by patient age, and provider
credentials are summarized in ►Table 3. Patients receiving
FQs were  51 years of age in 78/86 (89.7%) and 54/62 (87.1%)
in the control and intervention cohorts, respectively. Providers
with credentials of medical doctor (MD) initiated approximately 80% of all FQ orders in each cohort. Insufﬁcient
Applied Clinical Informatics
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Table 1 Baseline patient demographics characteristics
Parameter

Control cohort (n ¼ 350)

Intervention cohort (n ¼ 394)

All patients (n ¼ 744)

Age (y), mean (SD)

67.7 (15.0)

67.2 (14.4)

67.2 (14.4)

Female, n (%)

227 (64.9)

240 (60.9)

467 (62.8)

14 (16.3)

10 (16.1)

24 (16.2)

200 mg

—

1 (10.0)

1 (4.2)

250 mg

1 (7.1)

—

1 (4.2)

400 mg

8 (57.2)

5 (50.0)

13 (54.2)

500 mg

5 (35.7)

4 (40.0)

9 (37.5)

FQ, n (%)
Ciproﬂoxacin

Levoﬂoxacin

72 (83.7)

52 (83.9)

124 (83.8)

250 mg

3 (4.2)

2 (3.9)

5 (4.0)

500 mg

19 (26.4)

6 (11.5)

25 (20.2)

750 mg

50 (69.4)

44 (84.6)

94 (75.8)

PO

24 (27.9)

12 (19.4)

36 (24.3)

IV

62 (72.1)

50 (80.6)

112 (75.7)

Acute sinusitis

2 (0.6)

5 (1.3)

7 (0.9)

Acute bronchitis

319 (91.1)

366 (92.9)

685 (92.1)

Uncomplicated UTI

29 (8.3)

23 (5.8)

52 (7.0)

FQ route, n (%)

Indication, n (%)

Abbreviations: FQ, ﬂuoroquinolone; IV, intravenous; PO, per os; SD, standard deviation; UTI, urinary tract infection.

Table 2 Incidence of FQ orders following implementation of restriction and nonmodal messaging
Control cohort
(n ¼ 350)

Intervention cohort
(n ¼ 394)

p-Value

Acute sinusitis, acute bronchitis, and uncomplicated
UTI patients receiving a FQ

86 (24.6%)

62 (15.7%)

0.0035

Acute sinusitis, acute bronchitis, and uncomplicated
UTI patients receiving other therapy

264 (75.4%)

332 (84.1%)

Cephalosporin

150 (42.9%)

166 (42.1%)

0.9002

Macrolide

46 (13.1%)

86 (21.8%)

0.0027

Penicillin

37 (10.6%)

52 (13.2%)

0.3228

Abbreviations: FQ, ﬂuoroquinolone; UTI, urinary tract infection.

evidence existed to claim statistical association for either of
the secondary endpoints of interest.

Discussion
Documentation of antibiotic indication is one of the core
recommendations outlined by the CDC for hospital AS
programs.15 Such programs have demonstrated quality
improvement with standalone programmatic changes such
as the restriction of antimicrobial classes. Reports of vancomycin restriction requiring order rationale and pharmacist
intervention decreased inappropriate use from 39 to 16.8%
(p ¼ 0.005).11 As Joint Commission expands the scope of AS
standards, there may be room to further inﬂuence provider
Applied Clinical Informatics
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behavior by integrating nonmodal best-practice messaging
at critical junctures while still preserving workﬂow integrity.
Nonmodal messaging has also shown promise as an
independent, noninterruptive method of delivering bestpractice alerts. A small study of 24 junior doctors found
that providers shown a nonmodal alert were 3.2 times less
likely to make a prescribing error.16 Given the persistently
high rate of alert overrides, identifying modalities which
convey evidence-based recommendations to providers without creating untoward interruptions in workﬂow is a necessary step in further optimizing CDS. Reports from work
analysis and interviews have shown that nonmodal medical
alerts are appreciated by providers as a “safety net” for
situations outside the normal scope of their daily practice.17
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Fig. 2 Monthly ﬂuoroquinolone (FQ) order rates for acute bronchitis and uncomplicated urinary tract infection (UTI).

Table 3 FQ orders by provider type and patient age
Control cohort (n ¼ 86)

Intervention cohort (n ¼ 62)

All patients (n ¼ 148)

Doctor of medicine (MD)

69 (80.2)

49 (79.0)

118 (79.7)

Doctor of osteopathy (DO)

8 (9.3)

8 (12.9)

16 (10.8)

Physician assistant (PA)

9 (10.5)

4 (6.5)

13 (8.8)

Nurse practitioner (NP)

—

1 (1.6)

1 (0.7)

18–30

2 (2.3)

2 (3.2)

4 (2.7)

31–50

7 (8.0)

6 (9.7)

13 (8.8)

51–70

42 (48.3)

28 (45.2)

70 (47.3)

> 70

36 (41.4)

26 (41.9)

62 (41.9)

Provider type, n (%)

Patient age (y), n (%)

Abbreviation: FQ, ﬂuoroquinolone.

Considering FDA recommendations, analogous clinical
settings should consider performing internal assessments
of their AS and best-practice policies related to FQ. Institutions with existing FQ restriction policies may experience
added beneﬁt from the introduction of nonmodal alerts
within the restricted ordering process. Additional studies
are needed to examine the beneﬁt of nonmodal messaging
independently of restriction on FQ use in acute bronchitis,
acute sinusitis, and uncomplicated UTI.
We evaluated the effect of implementing FQ restriction
protocols with embedded nonmodal best-practice messaging. Initial study design sought to examine the effects of FQ
restriction and nonmodal messaging separately; however,
the informatics team implemented the nonmodal alert in
parallel with the restriction policy. The protocol was
amended to allow for a composite intervention due to the
unforeseen timing of the restriction policy implementation

which was not realized until data collection had already
commenced. FQ orders for acute bronchitis, acute sinusitis,
or uncomplicated UTI decreased from 24.6 to 15.7% following
implementation of nonmodal messaging and antibiotic
restriction. The composite effects of nonmodal messaging
combined with antibiotic restriction on clinician prescribing
behavior have not been examined in the current literature.
There are several potential limitations within this investigation. Chieﬂy, there existed an inability to directly account for
the inﬂuence of each element of the primary outcome on end
results. There were no patients receiving FQ for acute sinusitis
and limited numbers of patients receiving such therapy for
uncomplicated UTI. Due to delays and technical failures within
the initial study design, we were unable to study each element
of the primary outcome independently. There furthermore
may have been a time bias as it relates to the seasonal inﬂuence
of antibiotic prescribing patterns for infectious disease states
Applied Clinical Informatics
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such as pneumonia. Cephalosporin, macrolide, and penicillin
data were added as a control to help provide further insight
into temporal confounding (►Table 2). FQ order rates were
also broken down by month to show any stepwise patterns
existing pre- and postintervention and to more clearly elucidate temporal changes, as shown in ►Fig. 2. Nadirs for both
acute bronchitis and uncomplicated UTI occurred in the ﬁrst
month of the intervention. With the exception of a decreasing
trend in FQ orders for acute bronchitis, no clear prescribing
patterns were discernible potentially due to low numbers of
uncomplicated UTI patients meeting inclusion criteria for the
study. The observed rise in use of other antibiotics in parallel to
decreased FQ use give credence to potential intervention
effects rather than seasonal changes. Cohorts were not randomized or matched based on disease severity or previous
infections with resistant organisms. Some patient characteristics such as allergies, prior failure, and antibiotic susceptibility that may have justiﬁed FQ prescribing were not
accounted for. Finally, prescriber satisfaction with the nature
of nonmodal alert modalities as a function of streamlining
work ﬂow was not robustly assessed.

Implementation of hospital-wide antibiotic restriction with
integrated nonmodal messaging may have reduced FQ prescribing rates for acute bronchitis and uncomplicated UTI.
Additional rigorous testing is required to further deﬁne the
individual effects of the intervention.

Clinical Relevance Statement
Antimicrobial restriction protocols requiring documentation of speciﬁc indications for use are an opportunity to
examine nonintrusive CDS options within workﬂow such as
nonmodal messaging. The combination of nonmodal messaging plus restriction has demonstrated a reduced rate of
inappropriate prescribing of ﬂuoroquinolones for uncomplicated infections.

Multiple Choice Question
When implementing CDS to support antimicrobial restriction efforts, which method may effectively inﬂuence provider behavior without signiﬁcantly halting existing clinical
workﬂow?
Nonmodal alerts
Modal alerts
Hard stop alerts
Pop-up hyperlink
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